Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
GLTO 
Galecto Inc (GLTO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/24/2025: GLTO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $32
1 Year Target Price $32
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -78.48% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 43.73M USD | Price to earnings Ratio - | 1Y Target Price 32 |
Price to earnings Ratio - | 1Y Target Price 32 | ||
Volume (30-day avg) 2 | Beta 1.41 | 52 Weeks Range 2.01 - 33.60 | Updated Date 12/13/2025 |
52 Weeks Range 2.01 - 33.60 | Updated Date 12/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.11 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -43.54% | Return on Equity (TTM) -109.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 40848297 | Price to Sales(TTM) - |
Enterprise Value 40848297 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.46 | Shares Outstanding 1592521 | Shares Floating 1211028 |
Shares Outstanding 1592521 | Shares Floating 1211028 | ||
Percent Insiders 3.57 | Percent Institutions 13.38 |
Upturn AI SWOT
Galecto Inc
Company Overview
History and Background
Galecto Inc. is a clinical-stage biotechnology company focused on the development of novel therapies for fibrotic diseases and cancer. Founded in 2014, the company emerged from the University of Copenhagen and has since focused on its proprietary galectin-3 inhibitor platform. Key milestones include securing significant funding rounds and advancing its lead drug candidates into clinical trials.
Core Business Areas
- Fibrotic Diseases: Development of small molecule inhibitors targeting galectin-3 for the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis.
- Oncology: Exploration of galectin-3 inhibitors in combination therapies for various cancer indications, aiming to overcome treatment resistance and enhance anti-tumor immunity.
Leadership and Structure
Galecto Inc. is led by a management team with extensive experience in drug development and the biotechnology industry. The organizational structure is typical of a clinical-stage biotech, with emphasis on research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Galectin-3 Inhibitors (e.g., GB0139): Galecto's lead drug candidate, GB0139, is a small molecule inhibitor of galectin-3, a protein implicated in the pathogenesis of fibrosis and cancer. GB0139 is currently in clinical development for idiopathic pulmonary fibrosis (IPF). Market share data for early-stage drug candidates is not applicable. Competitors in the IPF space include companies developing anti-fibrotic agents.
Market Dynamics
Industry Overview
The biotechnology sector, particularly the area of fibrotic diseases and oncology, is characterized by high R&D investment, long development cycles, and significant unmet medical needs. The market for treatments for fibrotic diseases like IPF is growing, driven by an aging population and increased disease awareness.
Positioning
Galecto Inc. is positioned as a specialized biopharmaceutical company with a focus on a specific, yet broadly applicable, biological target (galectin-3). Its competitive advantage lies in its differentiated approach and its lead candidate's progression in clinical trials.
Total Addressable Market (TAM)
The TAM for fibrotic diseases, particularly IPF, is substantial and growing. Estimates vary, but the global IPF market is projected to reach billions of dollars in the coming years. Galecto's positioning is to capture a segment of this market with its targeted therapy, assuming successful clinical development and regulatory approval.
Upturn SWOT Analysis
Strengths
- Proprietary galectin-3 inhibitor platform
- Lead candidate (GB0139) in clinical development for IPF
- Experienced management team
- Focus on a validated target with potential in multiple indications
Weaknesses
- Clinical-stage company with no approved products
- Reliance on clinical trial success
- Limited financial resources compared to larger pharmaceutical companies
- Potential for high development costs and long timelines
Opportunities
- Growing unmet need in fibrotic diseases and certain cancers
- Potential for partnerships and collaborations with larger pharmaceutical companies
- Expansion of galectin-3 inhibitors to other fibrotic conditions and oncology indications
- Advancements in precision medicine and companion diagnostics
Threats
- Clinical trial failures or delays
- Intense competition in the pharmaceutical industry
- Regulatory hurdles and lengthy approval processes
- Patent expirations and generic competition for other treatments
- Changes in healthcare policy and reimbursement
Competitors and Market Share
Key Competitors
- Promedior, Inc. (PRDX) - (Hypothetical Symbol, Promedior is a private company)
- FibroGen, Inc. (FGEN)
- Gilead Sciences, Inc. (GILD)
Competitive Landscape
Galecto Inc. competes in a landscape with established pharmaceutical giants and other emerging biotechs. Its advantage lies in its specialized focus on galectin-3, while larger competitors have broader portfolios and greater resources. The success of GB0139 in clinical trials will be critical to establishing its competitive position.
Growth Trajectory and Initiatives
Historical Growth: Galecto's growth trajectory has been characterized by securing funding rounds to advance its pipeline and expanding its scientific team. The focus has been on pipeline advancement rather than revenue growth.
Future Projections: Future growth projections are highly dependent on the success of its ongoing clinical trials for GB0139 and the potential for its drug candidates to receive regulatory approval and achieve commercial success. Analyst estimates would be based on anticipated clinical outcomes and market potential.
Recent Initiatives: Recent initiatives likely involve the progression of GB0139 through Phase 2/3 clinical trials, potential expansion into new indications, and strategic partnerships or collaborations.
Summary
Galecto Inc. is a clinical-stage biotech with a promising galectin-3 inhibitor platform for fibrotic diseases and cancer. Its lead candidate, GB0139, shows potential in IPF. However, as an early-stage company, it faces significant risks related to clinical trial outcomes and funding. Success hinges on rigorous clinical development and navigating a competitive, R&D-intensive market. Close monitoring of trial data and strategic partnerships are crucial for its future.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company investor relations materials
- Biotechnology industry reports
- Financial news outlets
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Investing in biotechnology companies, especially clinical-stage ones, carries significant risk. Investors should conduct their own due diligence and consult with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galecto Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-10-29 | Co-Founder, President, CEO & Director Dr. Hans T. Schambye M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://galecto.com |
Full time employees 5 | Website https://galecto.com | ||
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.